截至2026年1月28日 10:09，中证医药及医疗器械创新指数(931484)下跌0.45%。成分股方面涨跌互现， 片仔癀领涨1.57%，兴齐眼药上涨1.00%，新和成上涨0.80%；华兰生物领跌。医疗创新ETF(516820)最 新报价0.36元。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评 ...

Group 1 - The core viewpoint of the news highlights a recent pullback in the biopharmaceutical sector, with the Huatai-PineBridge Biopharmaceutical ETF (159839) declining by 2.08% while maintaining high trading volume, with nearly 600 million yuan in transactions for the day [1][4] - The ETF has seen continuous inflows, with a net subscription of over 54 million shares today and a total of over 73 million yuan in the last 10 days [1] - The ETF tracks the Guozheng Biopharmaceutical Index, which includes sectors such as CXO, vaccines, chemical drugs, blood products, and medical aesthetics, with the vaccine sector currently accounting for 15.1% of the index [6] Group 2 - A significant research breakthrough was reported by the Wuhan Institute of Virology, confirming that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this high-mortality emerging infectious disease [3] - The biopharmaceutical ETF's major component stocks mostly experienced declines, with Watson Bio and Zhi Fei Bio dropping over 6%, while Sanofi Biopharma saw an increase of over 10% [4][5] - The latest performance forecast from Sanofi Biopharma indicates an expected net profit of approximately 2.9 billion yuan for 2025, representing a year-on-year growth of 311.35% [4] Group 3 - Data from Guoxin Securities indicates a decrease in pharmaceutical holdings among funds, with the overall pharmaceutical holding ratio at 7.97%, down by 1.71 percentage points from the previous quarter [7] - The largest sub-sector in pharmaceutical holdings is chemical preparations and other biological products, while the internet pharmacy and other biological products saw the most significant decline in holdings [9] - The JPM 2026 conference highlighted the acceleration of internationalization among Chinese pharmaceutical companies, with significant technological breakthroughs in areas such as ADC and GLP-1, leading to increased global competitiveness [10][11]

Group 1 - The core viewpoint of the article highlights the recognition of Guoquan Shihui in the Henan Provincial Government Work Report, emphasizing its role as a representative of new consumption and its innovative business model [2][3]. - Guoquan Shihui is identified as a leading one-stop meal product brand in China, offering a diverse range of products including hot pot, barbecue, beverages, single-serving meals, ready-to-cook packages, fresh food, Western cuisine, and snacks [3]. - By the end of 2025, Guoquan Shihui is projected to have over 11,500 stores nationwide and more than 60 million members, indicating its significant market presence and influence [3]. Group 2 - The report mentions the vigorous growth of the private economy in Henan, with 3.7 million new business entities established, highlighting the overall economic dynamism in the region [2]. - Key enterprises such as Muyuan, Yutong, and Hualan are noted for their strong performance, alongside emerging companies like Guoquan Shihui, which signifies a shift towards new business models in the province [2].

胖东来连续三年写入河南政府工作报告 中新网北京1月27日电(记者 袁秀月)近期，省级地方两会密集召开。记者注意到，胖东来、微短剧、"这 么近，那么美，周末到河北"等热词、热议话题出现在多地政府工作报告中，展现出各地发展的新活 力。 此次全运会由粤港澳首次联合举办，除了促进体育交流，还带动了"体育+文创""体育+文旅"热潮。据统 计，"喜洋洋""乐融融"爆款产品"一豚难求"，日销售峰值超300万元。目前，文创产品销售总额近10亿 元。 河北提及"这么近，那么美，周末到河北" 1月14日， 浙江省十四届人大四次会议在杭州开幕，浙江省省长刘捷作政府工作报告。 张斌 摄 "'这么近，那么美，周末到河北'火爆出圈"，1月26日，河北省十四届人大四次会议开幕，河北省政府 工作报告提及这句火爆出圈的文旅标语。 1月26日，河南省十四届人大四次会议开幕。在回顾"十四五"时期和2025年工作时，河南省政府工作报 告提出：民营经济活力迸发，新增经营主体370万户，牧原、宇通、华兰等一批龙头企业向强而跃，胖 东来、蜜雪冰城、锅圈食汇等一批新锐企业向新而生。 这是胖东来第三次、蜜雪冰城第二次被写入河南省政府工作报告。 有评论指出，" ...

Core Insights - The article highlights the significant achievements during the "14th Five-Year Plan" period, emphasizing economic resilience and development in Henan province despite challenges such as the pandemic and various risks. Group 1: Economic Performance - The province's GDP reached 6.66 trillion yuan, with total fiscal revenue at 701.9 billion yuan, and industrial enterprises' revenue at 5 trillion yuan. Retail sales of consumer goods totaled 2.9 trillion yuan, while total import and export value was 935.67 billion yuan [1] - The province has 11.605 million business entities, and the urbanization rate of the permanent population is 60% [1] Group 2: Industrial Transformation - Strategic emerging industries accounted for over 25% of the industrial added value, with seven major industrial clusters contributing over 70% to the industrial output [1] - The province boasts three global "lighthouse factories," 16 national-level excellent smart factories, 450 specialized and innovative "little giants," 59 manufacturing champions, 12,800 national high-tech enterprises, and 30,000 technology-based SMEs [1] Group 3: Rural Revitalization - The article mentions effective measures taken for rural revitalization, although specific details are not provided [1] Group 4: Reform and Opening Up - Strategic restructuring was achieved for 19 enterprises, including China Pingmei Shenma Group and Henan International Group. The establishment of new entities like Henan Rural Commercial Bank was also noted [1] - 3.7 million new business entities were added, with leading companies like Muyuan, Yutong, and Hualan expanding, alongside the emergence of new enterprises like Pandonglai and Mixue Ice City [1] Group 5: Environmental Improvement - The water quality of the Yellow River has met Class II standards for six consecutive years, and the water quality of the South-to-North Water Diversion project remains stable at Class II or above [1] Group 6: Social Welfare - Urban employment increased by 6.037 million, with 2.462 million rural laborers transferring to new jobs. The per capita disposable income of residents grew by an average of 6% annually [1]

Core Viewpoint - The vaccine sector is experiencing strong performance due to the emergence of Nipah virus cases in India, leading to increased investment in related biopharmaceutical ETFs [1][3]. Group 1: Market Performance - The biopharmaceutical ETF Huatai (159839) saw a significant increase of 2.13% with a trading volume exceeding 60 million yuan, marking a 133% increase compared to the previous period [1]. - The ETF received a net subscription of 16.5 million shares today, accumulating nearly 40 million yuan in the last five days [1]. - Major component stocks of the ETF showed positive performance, with Zhifei Biological rising nearly 15%, Watson Bio increasing over 11%, and Hualan Biological up nearly 7% [3]. Group 2: Nipah Virus Impact - Five confirmed cases of Nipah virus infection have been reported in West Bengal, India, including healthcare workers, with nearly 100 individuals under home quarantine [3]. - The Nipah virus can attack the lungs and brain, with symptoms including fever, headache, drowsiness, and confusion, and a mortality rate of over 40% [3]. - There is currently no specific vaccine or effective treatment for the Nipah virus [3]. Group 3: Vaccine Development and Innovation - Hualan Biological received approval for clinical trials of its recombinant shingles vaccine, while Zhifei Biological's CA111 injection has entered Phase I clinical trials [7]. - The vaccine industry is focusing on technological upgrades and exploring new markets, particularly in the Middle East [8]. - The growth of the vaccine sector is expected to be driven by the increasing immunization needs of the aging population, shifting focus from children to a broader demographic [8]. Group 4: mRNA Vaccine Developments - Recent positive clinical data from mRNA vaccine leaders indicate a breakthrough development window for therapeutic cancer vaccines [9]. - mRNA technology offers significant advantages over traditional methods, including rapid production capabilities and enhanced safety profiles [9].

Group 1 - The vaccine sector is experiencing a strong performance, with the medical ETF (159929) gaining 0.43% in the afternoon and surpassing a trading volume of 1.2 billion yuan, exceeding last Friday's total [1][3] - The medical ETF's constituent stocks are mostly in the green, with notable gains in vaccine stocks: Zhifei Biological up over 14%, Watson Bio up over 10%, and Hualan Biological up over 6% [3] - The top ten weighted stocks in the medical ETF account for 42.97% of the index, indicating a concentrated investment in key players within the pharmaceutical sector [7][8] Group 2 - Hualan Biological's subsidiary has received approval for clinical trials of its shingles vaccine, marking a significant breakthrough in its pipeline for preventive medicine, with expectations of increased demand due to an aging population [5] - Yiling Pharmaceutical forecasts a net profit of 1.2 to 1.3 billion yuan for 2025, indicating a turnaround from previous losses and signaling a critical operational inflection point [5] - The development of therapeutic cancer vaccines is entering a breakthrough phase, with mRNA technology leading the shift towards efficient and personalized immunotherapy, offering advantages in production, clinical safety, and strategic flexibility [6]

截至2026年1月26日 13:16，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，华兰生物领涨 5.00%，英科医疗上涨2.54%，华润三九上涨1.16%；南微医学领跌。医疗创新ETF(516820)下跌最新报 价0.37元。 生物医药概念午后快速拉升，消息面上，1月下旬，印度西孟加拉邦突发尼帕病毒疫情，已造成多名医 护人员感染，泰国、尼泊尔紧急升级防控。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 从资金净流入方面来看，医疗创新ETF近6天获得连续资金净流入，最高单日获得4053.70万元净流入， 合计"吸金"8499.86万元，日均净流入达1416.64万元。（数据来源：Wind） 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金 ...

Group 1 - The core viewpoint of the news highlights the performance of the medical innovation sector, with the China Securities Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Hualan Biological at a 0.90% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past six days, with a peak single-day net inflow of 40.54 million yuan, totaling 84.99 million yuan and an average daily net inflow of 14.17 million yuan [1] - Central China Television announced that Galaxy General Robotics will be the designated humanoid robot for the 2026 Spring Festival Gala, marking a significant milestone for the company established in May 2023, which focuses on a wide range of applications including retail, industrial, medical, and cultural tourism [1] Group 2 - The China Securities Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, collectively accounting for 63.75% of the index [2] Group 3 - The current medical device sector is at a turning point, with performance recovery expected in 2026, driven by new technologies such as AI in healthcare, brain-machine interfaces, and surgical robots, leading to a continuous revaluation of innovative products with global competitiveness [1]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][8]. Core Insights - The vaccine industry is undergoing a transformation from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term growth logic remains intact, driven by policy, demand, and technology [8][25]. - Recent developments in vaccine research and international expansion signal positive trends, with a shift in focus from child vaccination to a broader lifecycle approach due to demographic changes [3][7]. Summary by Sections Industry Performance - The vaccine sector has seen a relative performance decline of 25% over the past 12 months compared to the CSI 300 index, with absolute returns down by 2% [3]. - The vaccine index rose by 0.49% in the last week, while the overall pharmaceutical sector declined by 0.39% [4][5]. Company Developments - Huashan Vaccine received approval for clinical trials of its recombinant shingles vaccine [3]. - Kanghua Bio announced a projected net profit decline of 41.55%-52.09% for 2025, primarily due to decreased vaccine sales and market competition [3]. - Kexing Bio secured a two-year exclusive order for hepatitis A vaccine in Oman, marking a significant breakthrough in the Middle East market [3]. - Aimee Vaccine's 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials [3]. Market Dynamics - The industry is experiencing a shift in demand dynamics, with a notable decrease in newborn population affecting vaccine demand negatively, necessitating a re-evaluation of growth strategies [3][7]. - The vaccine sector's price competition is intensifying due to a high proportion of Me-too products, leading to significant price drops for some vaccines [7][22]. Valuation Metrics - The vaccine sector's PE (ttm) stands at 93.89X, with a PB (lf) of 1.82X, indicating a slight increase in valuation metrics compared to previous periods [6][18]. Investment Recommendations - The report suggests focusing on companies with strong innovation capabilities and differentiated product lines, particularly those with high technical barriers and international market strategies [8][25]. - Long-term investment opportunities are seen in companies that can leverage innovation and international expansion to navigate current market challenges [7][8].